"It could be with a pharma or biotech who either wants to move into DMD or orphan disease indications more generally speaking or sees the opportunity for ATL1102 as a novel anti-inflammatory drug in multiple disease indications including MS and long Covid."
Wayno,
If the area of interest for potential partner is both DMD and the broader anti-inflammatory market across multiple diseases...then it would be a pretty large Pharma who has the resources and $$$ to go broad and big.
In this case, the partnership deal becomes a little more expensive in my opinion, if PER give rights for the full potential to one player.
Interesting times...
PER is full of connections to CSL - there is Moses, Gittleson, McKenzie... not quite in their wheelhouse but never say never.
.
PER Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
(20min delay)